Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

10
results for

"Kyung-Ah Kim"

Article category

Keywords

Publication year

"Kyung-Ah Kim"

Editorial

Original Article

Viral hepatitis

Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
Clin Mol Hepatol 2023;29(3):779-793.
Published online May 15, 2023
DOI: https://doi.org/10.3350/cmh.2023.0110
Background/Aims
To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea.
Methods
We analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea.
Results
According to data from 2018–2020, the incidence of acute HBV infection in South Korea was 0.71 cases per 100,000 population; tthe linkage-to-care rate was only 39.4%. Among those who need hepatitis B treatment, the treatment rate was 67.3%, which was less than 80% reported in the WHO program index. The annual liver-related mortality due to HBV was 18.85 cases per 100,000 population, exceeding the WHO target of four; the most frequent cause of death was liver cancer (54.1%). The annual incidence of newly diagnosed HCV infection was 11.9 cases per 100,000 population, which was higher than the WHO impact target of five. Among HCV-infected patients, the linkage-to-care rate was 65.5% while the treatment rate was 56.8%, which were below the targets of 90% and 80%, respectively. The liver-related annual mortality rate due to HCV infection was 2.02 cases per 100,000 population.
Conclusions
Many of the current indicators identified in the Korean population did not satisfy the WHO criteria for validation of viral hepatitis elimination. Hence, a comprehensive national strategy should be urgently developed with continuous monitoring of the targets in South Korea.

Citations

Citations to this article as recorded by  Crossref logo
  • AI-Safe-C score: Assessing liver-related event risks in patients without cirrhosis after successful direct-acting antiviral treatment
    Huapeng Lin, Terry Cheuk-Fung Yip, Hye Won Lee, Xiangjun Meng, Jimmy Che-To Lai, Sang Hoon Ahn, Wenjing Pang, Grace Lai-Hung Wong, Lingfeng Zeng, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim
    Journal of Hepatology.2025; 82(3): 456.     CrossRef
  • Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021
    Si Yang, Yujiao Deng, Yi Zheng, Jing Zhang, Dongdong He, Zhijun Dai, Changcun Guo
    Hepatology International.2025; 19(2): 441.     CrossRef
  • Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults
    Donghee Kim, Won Kim, Aijaz Ahmed
    Clinical and Molecular Hepatology.2025; 31(1): e5.     CrossRef
  • Etiologic, epidemic, medical and economic aspects of hepatocellular carcinoma
    N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev
    Сибирский научный медицинский журнал.2025; 45(1): 6.     CrossRef
  • HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of dis
    Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2025; 31(2): e163.     CrossRef
  • Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiven
    Eun Sun Jang
    Clinical and Molecular Hepatology.2025; 31(2): 596.     CrossRef
  • Temporal and geospatial patterns of hepatitis C virus prevalence: a longitudinal examination using national health insurance service data in the Republic of Korea (2005–2022)
    Hwa Young Choi, Moran Ki
    BMC Public Health.2025;[Epub]     CrossRef
  • Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”
    Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2025; 31(2): e149.     CrossRef
  • Incidence of Osteopenia or Osteoporosis in Asian Patients With Chronic Hepatitis B
    Hye Won Lee, Sungshin Kwon, Yeo Rae Moon, Hyunjung Ahn, Juyeon Lee, Sang‐Hoon Ahn
    Journal of Gastroenterology and Hepatology.2025; 40(6): 1586.     CrossRef
  • A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles
    Lindsey Hiebert-Suwondo, Jana Manning, Rania A Tohme, Maria Buti, Loreta A Kondili, C Wendy Spearman, Nishi Prabdial-Sing, Victoria Turnier, Jeffrey V Lazarus, Imam Waked, John W Ward, Angelica Miranda, Aya Sugiyama, Behzad Hajarizadeh, Carlos Varaldo, Ca
    The Lancet Gastroenterology & Hepatology.2025; 10(7): 671.     CrossRef
  • Service delivery models and care cascade outcomes for people living with chronic hepatitis B: a global systematic review and meta-analysis
    Alexander J Stockdale, Bethany Holt, Ajeet Singh Bhadoria, Abhishek Sadasivan, Daniel Ikeda, Todd Pollack, Janus P Ong, Thuy Pham, David B Duong, Vy Nguyen, Gibril Ndow, Roger Chou, Philippa Easterbrook
    The Lancet Gastroenterology & Hepatology.2025; 10(11): 1013.     CrossRef
  • Prevalence, Clinical Characteristics, and Treatment Status of Hepatitis C Virus Infection among People Who Use Drugs in South Korea: A Prospective Multicenter Study
    Gwang Hyeon Choi, Young-Hoon Chon, Do Hoon Kwon, Sung Nam Jo, Og-Jin Jang, Kyung-Ah Kim, Dahye Baik, Eun Sun Jang, Sook-Hyang Jeong
    Gut and Liver.2025; 19(5): 725.     CrossRef
  • Etiological, Epidemiological, and Medical-Economic Aspects of Hepatocellular Carcinoma (A Review)
    N. A. Vlasova, V. I. Apanasevich, E. V. Eliseeva, S. S. Startsev
    Cell and Tissue Biology.2025; 19(6): 525.     CrossRef
  • Monitoring and evaluation of community interventions for viral hepatitis among migrants and refugees: a Delphi-based study
    Domenico Pascucci, Aina Nicolàs, Abdelrahman Taha, Jeffrey V Lazarus, Matteo Di Pumpo, Vittoria Tricomi, Francesco Di Berardino, Carlo La Vecchia, José A Perez-Molina, Giuseppe Colucci, Camila A Picchio, Angelo Maria Pezzullo, Stefania Boccia
    Journal of Global Health.2025;[Epub]     CrossRef
  • Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007–2021: a nationwide, multicentre, retrospective cohort study
    Won Sohn, Soo Young Park, Tae Hee Lee, Young Eun Chon, In Hee Kim, Byung-Seok Lee, Ki Tae Yoon, Jae Young Jang, Yu Rim Lee, Su Jong Yu, Won-Mook Choi, Sang Gyune Kim, Dae Won Jun, Joonho Jeong, Ji Hoon Kim, Eun Sun Jang, Hwi Young Kim, Sung Bum Cho, Byoun
    eClinicalMedicine.2024; 73: 102671.     CrossRef
  • Linvencovir: Paving the way for functional cure in hepatitis B
    Jiwon Yang, Jonggi Choi
    Clinical and Molecular Hepatology.2024; 30(2): 164.     CrossRef
  • Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis
    Makiko Kimura, Tomoki Nishikawa, Tetsuro Shimakami, Takeshi Terashima, Rika Horii, Masako Fukuda, Mika Yoshita, Noboru Takata, Tomoyuki Hayashi, Masaya Funaki, Kouki Nio, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Masao Honda, Junko Tanaka, Shuichi
    Global Health & Medicine.2024; 6(6): 404.     CrossRef
  • Activation of Nrf2 and FXR via Natural Compounds in Liver Inflammatory Disease
    Marta Belka, Aleksandra Gostyńska-Stawna, Maciej Stawny, Violetta Krajka-Kuźniak
    International Journal of Molecular Sciences.2024; 25(20): 11213.     CrossRef
  • Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
    Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2024; 30(4): 997.     CrossRef
  • Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
    Eun Ju Cho
    Clinical and Molecular Hepatology.2024; 30(4): 663.     CrossRef
  • 8,625 View
  • 222 Download
  • 18 Web of Science
  • Crossref

Erratum

Erratum to ‘Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in directacting antiviral failure in South Korea’ [Clin Mol Hepatol 2023;29:496-509]
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Seok Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong
Clin Mol Hepatol 2023;29(3):830-830.
Published online April 13, 2023
DOI: https://doi.org/10.3350/cmh.2022.0345e
Corrects: Clin Mol Hepatol 2023;29(2):496
  • 4,700 View
  • 32 Download

Original Articles

Viral hepatitis

Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Suk Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong
Clin Mol Hepatol 2023;29(2):496-509.
Published online March 6, 2023
DOI: https://doi.org/10.3350/cmh.2022.0345
Background/Aims
We used next-generation sequencing (NGS) to analyze resistance-associated substitutions (RASs) and retreatment outcomes in patients with chronic hepatitis C virus (HCV) infection who failed direct-acting antiviral agent (DAA) treatment in South Korea.
Methods
Using prospectively collected data from the Korean HCV cohort study, we recruited 36 patients who failed DAA treatment in 10 centers between 2007 and 2020; 29 blood samples were available from 24 patients. RASs were analyzed using NGS.
Results
RASs were analyzed for 13 patients with genotype 1b, 10 with genotype 2, and one with genotype 3a. The unsuccessful DAA regimens were daclatasvir+asunaprevir (n=11), sofosbuvir+ribavirin (n=9), ledipasvir/sofosbuvir (n=3), and glecaprevir/pibrentasvir (n=1). In the patients with genotype 1b, NS3, NS5A, and NS5B RASs were detected in eight, seven, and seven of 10 patients at baseline and in four, six, and two of six patients after DAA failure, respectively. Among the 10 patients with genotype 2, the only baseline RAS was NS3 Y56F, which was detected in one patient. NS5A F28C was detected after DAA failure in a patient with genotype 2 infection who was erroneously treated with daclatasvir+asunaprevir. After retreatment, 16 patients had a 100% sustained virological response rate.
Conclusions
NS3 and NS5A RASs were commonly present at baseline, and there was an increasing trend of NS5A RASs after failed DAA treatment in genotype 1b. However, RASs were rarely present in patients with genotype 2 who were treated with sofosbuvir+ribavirin. Despite baseline or treatment-emergent RASs, retreatment with pan-genotypic DAA was highly successful in Korea, so we encourage active retreatment after unsuccessful DAA treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Precision oncology through next generation sequencing in hepatocellular carcinoma
    Sayali Shinde, Carola Maria Bigogno, Ana Simmons, Nikita Kathuria, Aruni Ghose, Vedika Apte, Patricia Lapitan, Shania Makker, Aydin Caglayan, Stergios Boussios
    Heliyon.2025; 11(3): e42054.     CrossRef
  • Bridging the Gap in Elimination of Hepatitis C Virus among People Who Use Drugs in South Korea
    Beom Kyung Kim
    Gut and Liver.2025; 19(5): 635.     CrossRef
  • Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”
    Ming-Ying Lu, Ming-Lung Yu
    Clinical and Molecular Hepatology.2024; 30(2): 274.     CrossRef
  • 7,851 View
  • 175 Download
  • 3 Web of Science
  • Crossref

Viral hepatitis

A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective
Hye-Lin Kim, Kyung-Ah Kim, Gwang Hyun Choi, Eun Sun Jang, Moran Ki, Hwa Young Choi, Sook-Hyang Jeong
Clin Mol Hepatol 2022;28(1):91-104.
Published online November 5, 2021
DOI: https://doi.org/10.3350/cmh.2021.0236
Background/Aims
This study aimed to evaluate the cost-effectiveness of hepatitis C virus (HCV) screening compared to no screening in the Korean population from societal and healthcare system perspectives.
Methods
A published decision-tree plus Markov model was used to compare the expected costs and quality-adjusted life years (QALY) between one-time universal HCV screening and no screening in the population aged 40–65 years using the National Health Examination (NHE) program. Input parameters were obtained from analyses of the National Health Insurance claims data, Korean HCV cohort data, or from the literature review. The population aged 40–65 years was simulated in a model spanning a lifetime from both the healthcare system and societal perspectives, which included the cost of productivity loss due to HCV-related deaths. The incremental cost-effectiveness ratio (ICER) between universal screening and no screening was estimated.
Results
The HCV screening strategy had an ICER of $2,666/QALY and $431/QALY from the healthcare system and societal perspectives, respectively. Both ICERs were far less than the willingness-to-pay threshold of $25,000/QALY, showing that universal screening was highly cost-effective compared to no screening. In various sensitivity analyses, the most influential parameters on cost-effectiveness were the antibodies to HCV (anti-HCV) prevalence, screening costs, and treatment acceptance; however, all ICERs were consistently less than the threshold. If the anti-HCV prevalence was over 0.18%, screening could be cost-effective.
Conclusions
One-time universal HCV screening in the Korean population aged 40–65 years using NHE program would be highly cost-effective from both healthcare system and societal perspectives.

Citations

Citations to this article as recorded by  Crossref logo
  • Public value judgments about the criteria for reimbursement of medicines in South Korea
    Kyung-Bok Son
    Expert Review of Pharmacoeconomics & Outcomes Research.2025; 25(1): 53.     CrossRef
  • Economic evaluation of mass screening as a strategy for hepatitis C virus elimination in South Korea
    Hwa Young Choi, Kyung-Ah Kim, Bo Young Park, Bo Youl Choi, Moran Ki
    Journal of Infection and Public Health.2025; 18(3): 102662.     CrossRef
  • Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness
    Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2025; 31(1): 166.     CrossRef
  • Universal self-testing as a cost-effective weapon to eliminate hepatitis C virus in the Republic of Korea: Editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiven
    Eun Sun Jang
    Clinical and Molecular Hepatology.2025; 31(2): 596.     CrossRef
  • HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of dis
    Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2025; 31(2): e163.     CrossRef
  • Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe
    Blessing Dzingirai, Leolin Katsidzira, Maarten J. Postma, Marinus van Hulst, Nyashadzaishe Mafirakureva
    International Journal of Environmental Research and Public Health.2025; 22(4): 509.     CrossRef
  • Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
    Meiyu Wu, Jing Ma, Xuehong Wang, Sini Li, Chongqing Tan, Ouyang Xie, Andong Li, Aaron G Lim, Xiaomin Wan
    Clinical and Molecular Hepatology.2025; 31(2): 394.     CrossRef
  • Cost–benefit analysis of universal screening for HCV infection in China: a Markov modelling study
    Dachuang Zhou, Liangxiu Xu, Yimei Zhong, Zhehong Xu, Jun Wang, Yuntian Wang, Yiyang Gao, Jing Xie, Yuting Xia, Wenxi Tang
    BMC Health Services Research.2025;[Epub]     CrossRef
  • HCV elimination in hyperendemic areas: Experiences in Taiwan
    Chia-Yen Dai, Chung-Feng Huang, Wan-Long Chuang, Ming-Lung Yu
    Journal of the Formosan Medical Association.2025;[Epub]     CrossRef
  • Universal screening for HCV infection in China: An effectiveness and cost-effectiveness analysis
    Hua Zhou, Mengxia Yan, Datian Che, Bin Wu
    JHEP Reports.2024; 6(4): 101000.     CrossRef
  • Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center
    Jae Seung Lee, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Gastroenterology and Hepatology.2024; 39(6): 1155.     CrossRef
  • Improving the hepatitis C virus care cascade with the in‐hospital Reflex tEsting ALarm‐C (REAL‐C) model
    Jonggi Choi, Jina Park, Won‐Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Sujin Kwon, Sang‐Hyun Hwang
    Liver International.2024; 44(5): 1243.     CrossRef
  • A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe
    Blessing Dzingirai, Leolin Katsidzira, Vongai Mwanesani, Maarten Jacobus Postma, Marinus van Hulst, Nyashadzaishe Mafirakureva
    Expert Review of Pharmacoeconomics & Outcomes Research.2024; 24(5): 687.     CrossRef
  • Contemporary Insights into Hepatitis C Virus: A Comprehensive Review
    Malik Sallam, Roaa Khalil
    Microorganisms.2024; 12(6): 1035.     CrossRef
  • Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years
    Yewan Park, Seong-Kyun Na, Jae-Hyun Yoon, Sung-Eun Kim, Ji-Won Park, Gi-Ae Kim, Hyo-Young Lee, Young-Sun Lee, Jeong-Han Kim
    Medicina.2024; 60(7): 1132.     CrossRef
  • Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”
    Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2024; 30(4): 997.     CrossRef
  • Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies
    Yoko Yamagiwa, Keitaro Tanaka, Keitaro Matsuo, Keiko Wada, Yingsong Lin, Yumi Sugawara, Tetsuya Mizoue, Norie Sawada, Hidemi Takimoto, Hidemi Ito, Tetsuhisa Kitamura, Ritsu Sakata, Takashi Kimura, Shiori Tanaka, Manami Inoue, Sarah Krull Abe, Shuhei Nomur
    Scientific Reports.2023;[Epub]     CrossRef
  • Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
    Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
    Clinical and Molecular Hepatology.2023; 29(2): 433.     CrossRef
  • Comorbidities and the use of comedications among patients with chronic hepatitis C in Korea: A nationwide cross-sectional study
    Kyung Min Kwon, Jae-Jun Shim, Gi-Ae Kim, Bo Ok Kim, Helin Han, Hyun Jung Ahn
    The Korean Journal of Internal Medicine.2023; 38(3): 338.     CrossRef
  • Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
    Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
    Clinical and Molecular Hepatology.2023; 29(3): 779.     CrossRef
  • Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
    Soon Kyu Lee, Sung Won Lee, Hae Lim Lee, Hee Yeon Kim, Chang Wook Kim, Do Seon Song, U Im Chang, Jin Mo Yang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Seok-Hwan Kim, Myeong Jun Song, Jaejun Lee, Hyun Yang, Si Hyun Bae, Ji Won Han, Heechul Nam, Pil Soo
    The Korean Journal of Internal Medicine.2022; 37(6): 1167.     CrossRef
  • Finding Cases of Hepatitis C for Treatment Using Automated Screening in the Emergency Department is Effective, but What Is the Cost?
    David Stephen Prince, Julia Di Girolamo, Joseph Louis Pipicella, Melissa Bagatella, Tahrima Kayes, Frank Alvaro, Michael Maley, Hong Foo, Paul MacConachie Middleton, Miriam Tania Levy, Yu-Chen Fan
    Canadian Journal of Gastroenterology and Hepatology.2022; 2022: 1.     CrossRef
  • How to Optimize the Care Cascade of Hepatitis C Virus Infection
    Beom Kyung Kim
    Gut and Liver.2022; 16(6): 809.     CrossRef
  • 14,737 View
  • 233 Download
  • 23 Web of Science
  • Crossref

Case Report

Viral hepatitis

Acute pancreatitis associated with pegylated interferon-alpha-2a therapy in chronic hepatitis C
Jong Wook Choi, June Sung Lee, Woo Hyun Paik, Tae Jun Song, Jung Wook Kim, Won Ki Bae, Kyung-Ah Kim, Jung Gon Kim
Clin Mol Hepatol 2016;22(1):168-171.
Published online March 28, 2016
DOI: https://doi.org/10.3350/cmh.2016.22.1.168
Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Combination therapy of pegylated interferon-alpha (PEG-IFN-α) and ribavirin (RBV) is a current standard treatment for chronic HCV infection in Korea, which has considerable adverse effects. Acute pancreatitis is a rare complication of PEG-IFN-α administration. We report a case of a 62-year-old female who experienced acute pancreatitis after 4 weeks of PEG-IFN-α-2a and RBV combination therapy for chronic HCV infection. The main cause of the acute pancreatitis in this case was probably PEG-IFN-α rather than RBV for several reasons. A few cases have been reported in which acute pancreatitis occurred during treatment with PEG-IFN-α-2b. This is the first report of acute pancreatitis associated with PEG-IFN-α-2a in Korea.

Citations

Citations to this article as recorded by  Crossref logo
  • Drug-Induced Acute Pancreatitis: An Evidence-Based Classification (Revised)
    Jasmine Saini, Daniel Marino, Nison Badalov, Melanie Vugelman, Scott Tenner
    Clinical and Translational Gastroenterology.2023; 14(8): e00621.     CrossRef
  • Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations
    Dianna Wolfe, Salmaan Kanji, Fatemeh Yazdi, Pauline Barbeau, Danielle Rice, Andrew Beck, Claire Butler, Leila Esmaeilisaraji, Becky Skidmore, David Moher, Brian Hutton, Francisco X. Real
    PLOS ONE.2020; 15(4): e0231883.     CrossRef
  • Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China
    Bin Nie, Yongcan Guo, Kaijiong Zhang, Jinbo Liu, Sunguang Yun
    Archives of Virology.2020; 165(9): 2013.     CrossRef
  • Interferon β-induced acute pancreatitis: About two cases with literature review
    Imen Aouinti, Imen Hamza, Ons Charfi, Ghozlane Lakhoua, Sihem El Aidli, Riadh Daghfous, Ahmed Zaiem, Sarrah Kastalli
    Therapies.2019; 74(3): 449.     CrossRef
  • Systematic review of acute pancreatitis associated with interferon-α or pegylated interferon-α: Possible or definitive causation?
    Fateh Bazerbachi, Samir Haffar, Mohammad Tahir Hussain, Eric J. Vargas, Kymberly D. Watt, M. Hassan Murad, Suresh Chari, Barham K. Abu Dayyeh
    Pancreatology.2018; 18(7): 691.     CrossRef
  • Peginterferon-α-2a/ribavirin

    Reactions Weekly.2017; 1636(1): 256.     CrossRef
  • Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations
    Peleg Rider, Yaron Carmi, Idan Cohen
    International Journal of Cell Biology.2016; 2016: 1.     CrossRef
  • 13,163 View
  • 88 Download
  • 5 Web of Science
  • Crossref

Original Articles

Viral hepatitis

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
Sang Kyung Jung, Kyung-Ah Kim, So Young Ha, Hyun Kyo Lee, Young Doo Kim, Bu Hyun Lee, Woo Hyun Paik, Jong Wook Kim, Won Ki Bae, Nam-Hoon Kim, June Sung Lee, Yoon Jung Jwa
Clin Mol Hepatol 2015;21(1):41-48.
Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.41
Background/Aims

This study investigated the antiviral effects of tenofovir disoproxil fumarate (TDF) monotherapy in nucleos(t)ide analogue (NA)-naive and NA-experienced chronic hepatitis B (CHB) patients.

Methods

CHB patients treated with TDF monotherapy (300 mg/day) for ≥12 weeks between December 2012 and July 2014 at a single center were retrospectively enrolled. Clinical, biochemical, and virological parameters were assessed every 12 weeks.

Results

In total, 136 patients (median age 49 years, 96 males, 94 HBeAg positive, and 51 with liver cirrhosis) were included. Sixty-two patients were nucleos(t)ide (NA)-naïve, and 74 patients had prior NA therapy (NA-exp group), and 31 patients in the NA-exp group had lamivudine (LAM)-resistance (LAM-R group). The baseline serum hepatitis B virus (HBV) DNA level was 4.9±2.3 log IU/mL (mean±SD), and was higher in the NA-naïve group than in the NA-exp and LAM-R groups (5.9±2.0 log IU/mL vs 3.9±2.0 log IU/mL vs 4.2±1.7 log IU/mL, P<0.01). The complete virological response (CVR) rate at week 48 in the NA-naïve group (71.4%) did not differ significantly from those in the NA-exp (71.3%) and LAM-R (66.1%) groups. In multivariate analysis, baseline serum HBV DNA was the only predictive factor for a CVR at week 48 (hazard ratio, 0.809; 95% confidence interval, 0.729-0.898), while the CVR rate did not differ with the NA experience.

Conclusions

TDF monotherapy was effective for CHB treatment irrespective of prior NA treatment or LAM resistance. Baseline serum HBV DNA was the independent predictive factor for a CVR.

Citations

Citations to this article as recorded by  Crossref logo
  • Determinants of outcomes in patients with hepatitis B virus-decompensated cirrhosis
    Yi-Jie Huang, Jun-Sing Wang, Cheng-Hsu Chen, Shou-Wu Lee, Chung-Hsin Chang, Szu-Chia Liao, Yen-Chun Peng, Teng-Yu Lee, Tsai-Chung Li
    Scientific Reports.2025;[Epub]     CrossRef
  • Changes in liver stiffness values assessed using transient elastography in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study
    Heejin Cho, Yun Bin Lee, Yeonjung Ha, Young Eun Chon, Mi Na Kim, Joo Ho Lee, Hana Park, Kyu Sung Rim, Seong Gyu Hwang
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Switching from Tenofovir-Based Combination Therapy to Tenofovir Monotherapy in Multidrug-Experienced Chronic Hepatitis B Patients: a 5-Year Experience at Two Centers
    Jung Hun Kim, Jeong Han Kim, Won Hyeok Choe, So Young Kwon, Byung-chul Yoo, Eileen L. Yoon, Seong Hee Kang
    Antimicrobial Agents and Chemotherapy.2022;[Epub]     CrossRef
  • Antiviral Efficacy of Tenofovir Monotherapy in Children with Nucleos(t)ide-naive Chronic Hepatitis B
    Jae Young Choe, Jae Sung Ko, Byung-Ho Choe, Jung Eun Kim, Ben Kang, Kyung Jae Lee, Hye Ran Yang
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea
    Hyo Jun Ahn, Myeong Jun Song, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon, Haitao Guo
    PLOS ONE.2017; 12(1): e0170362.     CrossRef
  • The Effect of Naïve Tenofovir Dipivoxil Fumarate Monotherapy in Patients with Chronic Hepatitis B: 2-Year Results of a Real-world Single-center Study
    Sun Hee Oh, Min Ji Park, A Reum Cho, Joo Ah Lee, Joo Ho Park, Ki-Hyun Ryu, Hoon Sup Koo, Kyung Ho Song, Sun Moon Kim, Kyu Chan Huh, Young Woo Choi, Young Woo Kang, Tae Hee Lee
    The Korean Journal of Medicine.2017; 92(2): 162.     CrossRef
  • TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China
    Mingxing Huang, Guoli Lin, Hong Shi, Yuankai Wu, Yusheng Jie, Zhe Zhu, Yutian Chong
    BioMed Research International.2017; 2017: 1.     CrossRef
  • Clinical response to long-term tenofovir monotherapy in Korean chronic hepatitis B patients
    Eun-Hyung Yoo, Hyun-Jung Cho
    Clinica Chimica Acta.2017; 471: 308.     CrossRef
  • Efficacy of tenofovir-based rescue therapy in patients with lamivudine-resistant hepatitis B virus: A systematic review and meta-analysis
    Hui-Lian Wang, Xi Lu, Xudong Yang, Qilan Ning
    Clinics and Research in Hepatology and Gastroenterology.2016; 40(4): 447.     CrossRef
  • Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction
    Xiaojun Xu, Hong Thai, Kathryn M. Kitrinos, Guoliang Xia, Anuj Gaggar, Matthew Paulson, Lilia Ganova-Raeva, Yury Khudyakov, James Lara
    BMC Bioinformatics.2016;[Epub]     CrossRef
  • Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies
    Hyoung Su Kim
    World Journal of Gastroenterology.2015; 21(38): 10874.     CrossRef
  • Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon
    Soo Ki Kim, Soo Ryang Kim, Susumu Imoto, Madoka Tohyama, Yumi Otono, Tomoko Tamura, Ke Ih Kim, Mana Kobayashi, Aya Ohtani, Kayo Sugimoto, Aya Mizuguchi, Yukiko Hiramatsu, Masatoshi Kudo
    Oncology.2015; 89(Suppl. 2): 60.     CrossRef
  • 10,885 View
  • 86 Download
  • 16 Web of Science
  • Crossref

Viral hepatitis

Geographic differences in the epidemiological features of HCV infection in Korea
Kyung-Ah Kim, Sook-Hyang Jeong, Eun Sun Jang, Young Seok Kim, Youn Jae Lee, Eun Uk Jung, In Hee Kim, Sung Bum Cho, Mee-Kyung Kee, Chun Kang
Clin Mol Hepatol 2014;20(4):361-367.
Published online December 24, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.4.361
Background/Aims

The prevalence of hepatitis C virus (HCV) infection in Korea exhibits significant geographic variation, with it being higher in Busan and Jeonam than in other areas. The reason for this intranational geographic difference was investigated in this study by conducting a comparative analysis of the risk factors related to HCV infection among three geographic areas: the capital (Seoul), Busan, and the province of Jeolla.

Methods

In total, 990 patients with chronic HCV infection were prospectively enrolled at 5 university hospitals located in Seoul (n=374), Busan (n=264), and Jeolla (n=352). A standardized questionnaire survey on the risk factors for HCV infection was administered to these three groups of patients, and a comparative analysis of the findings was performed.

Results

The analysis revealed significant regional differences in exposure to the risk factors of HCV infection. By comparison with patients in Seoul as a control group in the multivariate analysis, patients in Busan had significantly more experience of invasive medical procedures, acupuncture, cosmetic procedures, and multiple sex partners. In contrast, patients in Jeolla were significantly older, and they had a higher prevalence of hepatocellular carcinoma, a lower prevalence of multiple sex partners, and had experienced fewer invasive procedures.

Conclusions

There was a significant geographic difference in the exposure to potential risk factors of HCV infection between patients from the three studied regions. This may explain the regional variation of the prevalence of HCV infection in Korea, and should be taken into account when planning strategies for the prevention and management of HCV infection.

Citations

Citations to this article as recorded by  Crossref logo
  • 부산광역시, 울산광역시, 경상남도 지역의 C형간염 발생 현황 및 특성, 2018-2023년
    선태 김, 지은 엄, 혁진 이, 유진 조, 슬기 강, 동한 이, 상은 이
    Public Health Weekly Report.2025; 18(6): 277.     CrossRef
  • 호남권 시도·시군구 단위의 C형간염 발생률 및 추이 분석, 2017-2021년
    영숙 최, 상용 엄, 정희 유
    Public Health Weekly Report.2023; 16(24): 743.     CrossRef
  • Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID
    Kyung-Ah Kim, Gwang Hyun Choi, Eun Sun Jang, Young Seok Kim, Youn Jae Lee, In Hee Kim, Sung Bum Cho, Moran Ki, Hwa Young Choi, Dahye Paik, Sook-Hyang Jeong
    Epidemiology and Health.2021; 43: e2021077.     CrossRef
  • Prevalence, Awareness, and Treatment of Hepatitis C Virus Infection in South Korea: Evidence from the Korea National Health and Nutrition Examination Survey
    Kyung-Ah Kim, June Sung Lee
    Gut and Liver.2020; 14(5): 644.     CrossRef
  • Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real‐world setting?
    Jae Hyun Yoon, Chung Hwan Jun, Ji Ho Seo, Hyun A Cho, Sung Bum Cho, Sung Kyu Choi, Ju Yeon Cho, Man Woo Kim, Sung Wook Lim
    Journal of Digestive Diseases.2019; 20(1): 31.     CrossRef
  • A large healthcare-associated outbreak of hepatitis C virus genotype 1a in a clinic in Korea
    Yoon-Seok Chung, Ju-yeon Choi, Myung Guk Han, Kye Ryeong Park, Su-Jin Park, Hyerim Lee, Youngmee Jee, Chun Kang
    Journal of Clinical Virology.2018; 106: 53.     CrossRef
  • Seropositivity of Hepatitis C Virus among Persons affected Leprosy in Korea
    Jong-Pill Kim, Kuk-Hyeong Kang, Jin-Mo Park
    Korean Leprosy Bulletin.2018; 51(1): 13.     CrossRef
  • KASL clinical practice guidelines: management of hepatitis C

    Clinical and Molecular Hepatology.2016; 22(1): 76.     CrossRef
  • Recent outbreaks of hepatitis C virus infection in Korea and strategy for prevention
    In Hee Kim
    Journal of the Korean Medical Association.2016; 59(12): 912.     CrossRef
  • Recent outbreaks of hepatitis C virus infection in Korea and strategy for prevention
    In Hee Kim
    Journal of the Korean Medical Association.2016; 59(12): 912.     CrossRef
  • Clinical Characteristics of Defectors from North Korea Visiting a Single Tertiary Hospital in South Korea
    Sun Young Ann, Sung Hyeok Ryou, Suk Bae Kim
    Korean Journal of Medicine.2015; 89(1): 54.     CrossRef
  • Epidemiology of Hepatitis C Virus Infection in Korea
    Sook-Hyang Jeong
    Korean Journal of Medicine.2015; 88(6): 630.     CrossRef
  • 9,844 View
  • 64 Download
  • 6 Web of Science
  • Crossref

Review

The diagnosis and treatment of primary biliary cirrhosis
Kyung-Ah Kim, Sook-Hyang Jeong
Korean J Hepatol 2011;17(3):173-179.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.173

Primary biliary cirrhosis (PBC) is a slowly progressive cholestatic liver disease of autoimmune etiology. The initial presentation of PBC is various from asymptomatic, abnormal liver biochemical tests to overt cirrhosis. The diagnosis of PBC is based on cholestatic biochemical liver tests, presence of antimitochondrial antibody and histologic findings of nonsuppurative destructive cholangitis. Although the diagnosis is straightforward, it could be underdiagnosed because of its asymptomatic presentation, or underrecognition of the disease. UDCA in a dose of 13-15 mg/kg is the widely approved therapy which can improve the prognosis of patients with PBC. However, one-third of patients does not respond to UDCA therapy and may require liver transplantation. Every effort to diagnose PBC in earlier stage and to develop new therapeutic drugs and clinical trials should be made.

Citations

Citations to this article as recorded by  Crossref logo
  • Alcohol Consumption and Autoimmune Diseases
    Sergio Terracina, Brunella Caronti, Marco Lucarelli, Silvia Francati, Maria Grazia Piccioni, Luigi Tarani, Mauro Ceccanti, Micaela Caserta, Loredana Verdone, Sabrina Venditti, Marco Fiore, Giampiero Ferraguti
    International Journal of Molecular Sciences.2025; 26(2): 845.     CrossRef
  • Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis
    Dong-Won Ahn
    The Korean Journal of Gastroenterology.2020; 75(5): 246.     CrossRef
  • Detection of Autoantibodies Against Nucleoporin p62 in Sera of Patients With Primary Biliary Cholangitis
    Alicja Bauer, Andrzej Habior
    Annals of Laboratory Medicine.2019; 39(3): 291.     CrossRef
  • Amyotrophic Lateral Sclerosis and Primary Biliary Cirrhosis Overlap Syndrome: Two Cases Report
    Haibo Zhang, Yaling Liu, Zhenfei Li, Na Liang, Xiaomeng Zhou, Xiangyu Nie, Ting Zhang, Weijing Qi
    Frontiers in Neurology.2019;[Epub]     CrossRef
  • Primary biliary cholangitis: an update on treatment
    Fatima Bibi
    Gastrointestinal Nursing.2018; 16(Sup10): S10.     CrossRef
  • Making Sense of Autoantibodies in Cholestatic Liver Diseases
    Simona Marzorati, Pietro Invernizzi, Ana Lleo
    Clinics in Liver Disease.2016; 20(1): 33.     CrossRef
  • Novel Therapies on Primary Biliary Cirrhosis
    Frank Czul, Cynthia Levy
    Clinics in Liver Disease.2016; 20(1): 113.     CrossRef
  • Associations Between Magnetic Resonance Imaging Findings and Scores of Liver Function and Histology in Patients with Primary Biliary Cirrhosis
    Dan Han, Wen He
    Applied Magnetic Resonance.2015; 46(7): 731.     CrossRef
  • Traditional Iranian medicine: The use of the Canon of medicine by Avicenna to treat ascites
    Jamileh Jafari Mahdavi, Jale Aliasl, Mohammad Javad Ehsani, Mohammad Kamalinejad, Latif Gachkar, Rasool Choopani
    European Journal of Integrative Medicine.2015; 7(6): 674.     CrossRef
  • The Association between Bile Salt Export Pump Single-Nucleotide Polymorphisms and Primary Biliary Cirrhosis Susceptibility and Ursodeoxycholic Acid Response
    Rui-rui Chen, Yuan-jun Li, Xin-min Zhou, Lu Wang, Juan Xing, Shuang Han, Li-na Cui, Lin-hua Zheng, Kai-chun Wu, Yong-quan Shi, Zhe-yi Han, Ying Han, Dai-ming Fan
    Disease Markers.2014; 2014: 1.     CrossRef
  • Non-Alcoholic Fatty Liver Disease: Diagnosis and Evaluation of Disease Severity
    Raika Jamali
    Thrita Journal of Medical Sciences.2013; 2(2): 43.     CrossRef
  • Review of overlap syndromes of autoimmune liver diseases. Difficulties in the diagnosis and treatment
    Krisztina Hagymási, Zsolt Tulassay
    Orvosi Hetilap.2013; 154(24): 923.     CrossRef
  • Johan Turi’s animal, mineral, vegetable cures and healing practices: an in-depth analysis of Sami (Saami) folk healing one hundred years ago
    Thomas A DuBois, Jonathan F Lang
    Journal of Ethnobiology and Ethnomedicine.2013;[Epub]     CrossRef
  • Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ A randomized open‐label controlled study
    Moon Young Kim, Mee Yon Cho, Soon Koo Baik, Phil Ho Jeong, Ki Tae Suk, Yoon Ok Jang, Chang Jin Yea, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Byung Su Yoo, Jang Young Kim, Min Seob Eom, Seung Hwan Cha, Sei Jin Chang
    Liver International.2012; 32(6): 977.     CrossRef
  • 12,968 View
  • 98 Download
  • Crossref
The Korean Journal of Hepatology Elsewhere

Citations

Citations to this article as recorded by  Crossref logo
  • Recent advances and future directions in the management of hepatitis C infections
    Victoria Belousova, Ahmed A. Abd-Rabou, Shaker A. Mousa
    Pharmacology & Therapeutics.2015; 145: 92.     CrossRef
  • 7,539 View
  • 39 Download
  • Crossref